- Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
-
Ro J, Cheng FT, Sriuranpong V, Villalon A, Smruti BK, Tsang J, Yap YS, Asian Working Group for Eribulin Clinical Guide
- KMID: 2176316
- J Breast Cancer.
- 2016 Mar;19(1):8-17.
- doi: 10.4048/jbc.2016.19.1.8
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories
-
Ithimakin S, Parinyanitikul N, Kim SB, Yap YS, Tsang J, Soong IS, Ozaki Y, Ohno S, Ono M, Chan JJ, Cheng HCS, Dejthevaporn T, on behalf of BIG-Asia Collaboration
- KMID: 2530764
- J Breast Cancer.
- 2022 Jun;25(3):207-217.
- doi: 10.4048/jbc.2022.25.e21
Purpose: Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
-
Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel , Ro J
- KMID: 2460601
- Cancer Res Treat.
- 2019 Oct;51(4):1527-1539.
- doi: 10.4143/crt.2018.598
PURPOSE: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian... -
- CITED
-
- Close
- SHARE
-
- Close
